Ozempic vs Wegovy vs Mounjaro: The Differences

When people talk about the weight-loss injection, three names usually come up: Ozempic, Wegovy and Mounjaro. In the media, in forums and among friends they are often lumped together, yet behind them lie different active ingredients, different manufacturers and different approvals. Anyone who wants to understand what is currently being discussed first needs clarity about which medicine is which. This article gives a factual overview of the three preparations: active ingredient, mechanism of action, approval, costs in Germany and what is currently happening in development. A note in advance: all of these are prescription-only medicines that belong in the hands of a doctor.

Which active ingredient is behind Ozempic, Wegovy and Mounjaro?

The brand names say little about the substance that actually works. Ozempic and Wegovy contain the same active ingredient: semaglutide. Both come from the Danish manufacturer Novo Nordisk. Mounjaro contains a different active ingredient, tirzepatide, and comes from the US company Eli Lilly. Even here it becomes clear why equating the three names is misleading: two of them are at their core the same medicine under different brands, the third is an active ingredient in its own right.

Ozempic is primarily approved for the treatment of type 2 diabetes. The fact that it became known for weight loss is due to a side effect: patients lost weight during treatment. As a result, Ozempic was in some cases prescribed outside its approval, i.e. off-label, purely for weight reduction. Off-label use takes place outside the tested and approved area of application and is the responsibility of the treating doctor.

Wegovy is Novo Nordisk's answer to precisely this gap. It contains the same active ingredient, semaglutide, but is specifically approved for the treatment of obesity, i.e. for weight reduction in severely overweight people. In the European Union, Wegovy has been approved since early 2022; in Germany it has been available since mid-2023. So anyone talking about the injection specifically for weight loss strictly means Wegovy, not Ozempic.

Mounjaro is the youngest of the three names and is based on tirzepatide. This active ingredient works through an additional point of attack in the body and has shown a stronger weight reduction than semaglutide in studies. More on this in the next section, because the difference in the mechanism of action is the actual reason for the different results.

How do the weight-loss injections differ in their mechanism of action?

Semaglutide belongs to the group of GLP-1 receptor agonists. GLP-1 stands for a gut hormone produced by the body that is released after eating. The active ingredient mimics this hormone and thereby intervenes at several points: it enhances the feeling of satiety, slows gastric emptying and reduces the appetite. In sum, those affected eat less, often significantly less. In studies, energy intake fell by up to 40%.

Tirzepatide, the active ingredient in Mounjaro, goes one step further. It works not only at the GLP-1 receptor but additionally at a second receptor called GIP. This is why it is referred to as a dual mechanism of action. This double effect is considered one reason why tirzepatide has led to a stronger weight reduction than semaglutide alone in studies.

Important for understanding: a stronger effect in studies is no statement about what the right medicine is for an individual person. Tolerability, pre-existing conditions, concomitant medication and the individual treatment goal play an equally large role. Which preparation is suitable is decided by the treating doctor, not by the study data on paper.

What does the weight-loss injection cost in Germany, and do you need a prescription?

All three preparations are prescription-only. They are not available without a prescription, and for good reason: dosage, tolerability and possible risks must be medically supervised. The decisive point for many, however, is the question of cost, and this is often reported imprecisely.

The statutory health insurance funds do not cover the weight-loss injection when it is used solely for weight reduction. Anyone who wants to lose weight without an additional medical indication needs a private prescription and pays for it themselves. It is different with a diabetes condition: here a prescription covered by health insurance is possible, because the medicine then serves to treat the underlying illness.

For those paying themselves, and always only on medical prescription, the costs differ depending on the preparation and dose. The monthly costs start at roughly 276 euros for Wegovy and at roughly 490 euros for Mounjaro. These are ongoing costs, because the therapy is designed for the long term. After stopping, most people gain weight again; that is one of the uncomfortable truths of this treatment. What happens after stopping and how the yo-yo effect can be limited is dealt with in a separate article of the series.

What is currently developing in weight-loss medicines?

The field is moving fast, and some developments are already reality or on the verge of it. Oral semaglutide is not fundamentally new: as Rybelsus, the active ingredient has already been used in tablet form for the treatment of type 2 diabetes since around 2020. What is new is a higher-dosed variant from Novo Nordisk, developed specifically for weight reduction, i.e. the active ingredient from Ozempic and Wegovy as a tablet instead of an injection. For such an active ingredient to be absorbed sufficiently in the gastrointestinal tract at all, a special absorption technology is needed.

At Eli Lilly, work is being done on orforglipron, an oral GLP-1 active ingredient of a different design. It is a so-called small molecule which, unlike the previous active ingredients, is intended to manage without fasting or intake restrictions. An approval is considered possible over the course of 2026, but has not yet been finally decided.

Further back in the pipeline are two candidates with high expectations. Retatrutide from Eli Lilly is a so-called triple agonist that acts on three receptors at once. In early study data, a weight reduction towards 24 to 26% was seen. CagriSema from Novo Nordisk combines two active ingredients and achieved roughly 20% weight reduction after 68 weeks in studies; a regulatory decision is expected in 2026.

These figures sound impressive but should be read soberly. Early study data are no promise for the market, and a higher weight reduction does not automatically mean a better safety profile. Which of these prevails and how it proves itself in broad use remains to be seen.

Which side effects and risks are known?

The most common side effects affect the gastrointestinal tract: nausea, vomiting, a feeling of fullness, diarrhoea and constipation. They usually appear at the start of treatment and after a dose increase and often decline over time. A slow, gradual increase of the dose usually improves tolerability, which is why supervision by a doctor is also central here. How these side effects make themselves felt depending on the active ingredient and how smart eating helps through the transition phase is shown in the article on side effects and nutrition.

Rarer but more serious risks, according to approval documents and studies, include acute inflammation of the pancreas, gallbladder disease and dehydration-related kidney damage. For perspective it is important: large review papers do not support a general pancreatitis risk of the entire active-ingredient class, and rapid weight loss is in itself already a risk factor for gallbladder problems.

On the subject of the thyroid, there are indications that semaglutide can lower the TSH value. In animal studies with rodents, C-cell tumours of the thyroid occurred; in humans this connection has so far not been confirmed. Naming such data honestly also means making their limits clear: animal data cannot be transferred one to one to humans.

One point runs through all the risk considerations: the long-term data are limited. The longest controlled study data reach back roughly four years for semaglutide and about two years for tirzepatide. Correspondingly little that is reliable can be said about the effect and safety over decades. This too is a reason to understand the treatment as a medically supervised decision and not as a lifestyle product.

FAQ

Are Ozempic and Wegovy the same?

Ozempic and Wegovy both contain the active ingredient semaglutide and both come from Novo Nordisk. The difference lies in the approval: Ozempic is primarily approved for the treatment of type 2 diabetes, Wegovy is specifically authorised for the treatment of obesity. For pure weight loss, Ozempic is often used off-label, while Wegovy is the approved variant for this. Which preparation comes into question is clarified by medical treatment.

What is the difference between Mounjaro and Ozempic?

The most important difference lies in the active ingredient. Ozempic contains semaglutide and works at the GLP-1 receptor. Mounjaro contains tirzepatide and additionally works at the GIP receptor, so it has a dual mechanism of action. In studies, tirzepatide led to a stronger weight reduction than semaglutide. Both are prescription-only, and the choice is made by the treating doctor.

Which weight-loss injection works the strongest?

According to the available studies and the data filed with the approval authority EMA, tirzepatide, the active ingredient in Mounjaro, showed a stronger weight reduction than semaglutide. But a stronger effect in studies says nothing about which medicine is the best for an individual person: the strongest does not automatically mean the best for you. Tolerability, pre-existing conditions and the treatment goal are equally decisive, and this weighing-up is decided by medical supervision, not by a comparison on your own.

Does health insurance pay for the weight-loss injection?

The statutory health insurance funds do not cover the weight-loss injection when it is used solely for weight reduction. In this case a private prescription is needed, and you bear the costs yourself. With a diabetes condition, a prescription covered by health insurance is possible, because the medicine then serves to treat the underlying illness.

What does the weight-loss injection cost per month?

Is the weight-loss injection also available as a tablet?

Yes, the active ingredient semaglutide is also available in tablet form. As Rybelsus, it has already been used for the treatment of type 2 diabetes since around 2020; what is new is a higher-dosed variant developed specifically for weight reduction. For the active ingredient to be absorbed, a special absorption technology is used. Further oral active ingredients such as orforglipron are in development; an approval here is still pending. A tablet, too, remains a prescription-only medicine.

How to read on in this series

This article only gives an overview of the medicines themselves. How a treatment is sensibly accompanied, and what to consider with nutrition, nutrient supply and muscle preservation, is dealt with in the other articles of the series. The overview is given by the complete guide to the weight-loss injection.

Anyone who wants to know which vitamins and minerals can become scarce during the treatment will find the explanation in the article on nutrient deficiencies on the weight-loss injection. Which food supplementation is scientifically justified in this context and which is just hype is clarified in the article on supplements under the weight-loss injection.

Disclaimer:

This article is for informational purposes only and does not replace medical advice, diagnosis, or treatment by a physician or pharmacist. The information provided here should not be used for self-diagnosis or self-treatment. Food supplements are no substitute for a balanced, varied diet and a healthy lifestyle. For any health questions or complaints, please always consult a doctor you trust. Fifty Five accepts no liability for any inconvenience or harm resulting from the use of the information presented here.